France is making waves in AI-driven healthcare—scaling fast, innovating boldly, and balancing Silicon Valley agility with EU oversight. But is this the winning formula? In the latest episode in our European Healthcare Innovation Roadshow serie

How can we drive medical innovation while keeping healthcare costs in check? In the second episode of our European Healthcare Innovation Roadshow series, Ollie and Jack are joined by special guest Rosie Beacon from Reform UK to tackle this paradox

In this episode, Ollie, Jack, and Nathan discuss the rise of Barcelona as a hotbed for Digital Health Innovation. They discuss digital health trends, how Barcelona has achieved such success, and what lessons the rest of the world can learn.

For the final installment in Vynamic\’s 2025 health industry outlook series, Jen is joined by Vynamic’s Head of Life Sciences, Karen Baldry, and Head of Life Sciences Europe, Gemma Pfister, to focus on the Life Sciences industry – the trends most

For the second installment in Vynamic’s 2025 health industry outlook series, Jen is joined by Vynamic’s Head of Health Services, Ryan Hummel, and Director, Vish Kaushik, to focus on the Health Services industry – the trends most impacting provider

As 2025 begins, the health industry is charging forward into a transformative era. Faced with unprecedented challenges and opportunities, leaders are rethinking how health care is delivered, financed, and optimized. On this episode, Jen and Mind

When it comes to deploying AI technologies, there are both technical and ethical considerations – in healthcare, given the critical and sensitive data and decisions at play, these can be magnified nearly exponentially. Jen is joined by Vynamic’s A

On November 6th, Donald Trump was announced as the 47th President of the United States, returning to the White House for his second term. In this episode, Jen, Mindy, and Ryan discuss the potential changes to the healthcare industry that Republica

Last month, Life Sciences marketing, commercial and medical leaders from across the country gathered at Reuter’s Pharma Customer Engagement to address current challenges and share industry best practices. In this episode, Jen is joined by Vynamic’

With the first round of CMS price negotiations behind us, and the next list of targets to be released in February 2026, it’s clear that theorized implications from the Inflation Reduction Act are becoming realities for the life sciences industry.